Advanced melanoma survival improves significantly when immunotherapy is given before targeted therapy

A clinical trial showed a remarkable 20 percent advantage in the two-year overall survival rate for people with advanced melanoma who first received immunotherapy (72 percent survival rate) versus those who initially got targeted therapies (52 percent survival rate). Progression-free survival, where the cancer is stable or improving, was also trending in favor of those who started on immunotherapy.

from Latest Science News -- ScienceDaily https://ift.tt/NFrCxJj

Comments

Popular posts from this blog

Seismic study reveals key reason why Patagonia is rising as glaciers melt

New method to detect and visualize sperm cells recovered from forensic evidence